Objective: To determine the frequency of immunohistochemically expression of
Glypican-3 in hepatocellular carcinoma on liver biopsies.
Objective: To determine the diagnostic accuracy of
Glypican-3 in differentiating hepatocellular carcinoma from metastatic liver tumours while taking histopathology as the gold standard.
AFTV has been shown to induce cytotoxic T lymphocytes specific to
glypican-3, the protein frequently expressed in HCC [18].
Glypican-3 is a proteoglycan that is attached to the cell surface and plays an important role in cellular growth, differentiation, and migration.
Glypican-3 (GPC3) may be the most promising among the specific molecular targets for HCC.
Dabeva, "The oncofetal protein
glypican-3 is a novel marker of hepatic progenitor/oval cells," Laboratory Investigation, vol.
On staining of hepatocytes (Figure 7(c)), alpha-fetoprotein (AFP),
glypican-3, and arginase-1 were negative.
Antibodies included synaptophysin (Syn), chromogranin A (CgA), CD56, phosphoenolpyruvate carboxykinase (PCK), cytokeratin 19 (CK19), cytokeratin 7 (CK7), epithelial membrane antigen (EMA),
glypican-3, and hepatocyte.
The hepatoid adenocarcinoma component usually expresses AFP and some may also express HepPar-1 [1, 11], arginase-1 [11], and
glypican-3 [11].
Immunohistochemical examinations demonstrated that the carcinoma cell was positive for vimentin, AE1/AE3 (focal), CAM5.2 (focal), CK7 (focal), and CK19 (focal) but negative for EMA, S-100, SMA, desmin, H-caldesmon, DOG-1, HepPar-1,
glypican-3, CD34, CD117, PDGFR-Alpha, CK20, bile stain, iron, and mucicarmine.
Some alternative immunological markers, such as HepPar1,
glypican-3, CD34, and AFP, are helpful in differential diagnosis.[6],[7],[25],[26],[27]
Glypican-3.--Glypican-3 (GPC3) is an oncofetal protein that can be detected in 70% to 80% of HCCs but not in benign hepatocellular lesions, such as hepatocellular adenoma.